Showing posts with label UK. Show all posts
Showing posts with label UK. Show all posts

Wednesday, 17 February 2016

PubMed Update November 2015 - January 2016

We have 35 articles for your viewing this time, with apologies for the delay in getting this out. Thanks to Traci Green for offering to help out and for reviewing this post.


Becker WC, Merlin JS, Manhapra A, Edens EL.
Addict Sci Clin Pract. 2016 Jan 28;11(1):3. doi: 10.1186/s13722-016-0050-0.
Comment: Fascinating article. Worth a read if you’re interested in management of pain and opioids.

Harocopos A, Allen B, Paone D.
Int J Drug Policy. 2015 Dec 29. pii: S0955-3959(15)00374-6. doi: 10.1016/j.drugpo.2015.12.021. [Epub ahead of print]
Comment: Great to see some of the path from prescription opioids to heroin. Makes sense that first step is moving from a drug co-formulated with acetaminophen.

Samuels EA, Dwyer K, Mello MJ, Baird J, Kellogg A, Bernstein E.
Acad Emerg Med. 2016 Jan 27. doi: 10.1111/acem.12910. [Epub ahead of print]
Comment: To get EDs to enhance practices will require pressure from the top.

4) Internal Medicine Resident Knowledge, Attitudes and Barriers to Naloxone Prescription in Hospital and Clinic Settings.
Wilson JD, Spicyn N, Matson P, Alvanzo A, Feldman L.
Subst Abus. 2016 Jan 28:0. [Epub ahead of print]
Comment: Nice article from Baltimore finding that young physicians are ready and willing to prescribe naloxone, but aren’t routinely doing so yet.


5) Clinical provision of improvised nasal naloxonewithout experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?
Strang J, McDonald R, Tas B, Day E.
Addiction. 2016 Feb 3. doi: 10.1111/add.13209. [Epub ahead of print]
Comment: There are significant issues with this proscriptive publication. First, as noted in the disclosures, the author has interest as an inventor in a patent on a new formulation of naloxone owned by his employer that would address the concerns upon which he bases his conclusions. This is a quite a conflict of interest for an academic commentary that directs clinicians in how to act.

Second, a quote from the Discussion section describes where the authors have gone off course:

“In this situation [lay naloxone administration] the failure of effect of i.n. naloxone, for whatever reason, can delay the time to naloxone injection until an ambulance arrives.”

And what would occur if there was no naloxone, besides delay in the time of naloxone administration until an ambulance arrives? As we know from experience, getting a needle into places like pre-release prison is impossible in most settings – whereas getting the nasal device was achievable. While we have long sought a superior nasal device, the absence of such a product did not obviate the benefits of nasal naloxone. The authors’ views in this case are, I believe, inconsistent with public health aims.

Third, the authors ignore the years of on-the-ground experience that emergency medical providers in the United States have with the jerry-rigged nasal naloxone device in question. Numerous systems adopted the product because it took the risk of needle-sticks out of the equation and was as - or nearly as - effective as when injected. Some investigators have suggested, and many anesthesiologists would agree, that this relatively low dose of naloxone may be all that is needed in most cases since the goal isn't to restore a Glasgow Coma Scale of 15 - that may actually complicate lay management of overdose - but to restore breathing. (On a slight tangent, some have suggested the fascinating hypothesis that the clinical response to nasal naloxone - which is better than would be expected based on peripheral blood concentrations - may be due to exposure to naloxone through the cribriform plate directly into the central nervous system.) 

Finally, to suggest that there are ethical concerns in having used this device to expand access because it was not the perfect device ignores the reality of overdose – this isn’t something we can wait to address until everything is perfect. People’s lives are on the line. Public health providers would have been at far greater fault if they had done nothing. The lead author, based in England where naloxone provision has long been delayed, should be well aware of this problem.

This "debate" seems particularly odd from the U.S. perspective, where off-label prescription and use of medications is authorized by the Food and Drug Administration and common practice. This paper is apparently the first salvo in a discussion that will involve four additional papers coming out in April.

[No authors listed]
Med Lett Drugs Ther. 2016 Jan 4;58(1485):1-2. No abstract available.
Comment: As a follow-up to the oddly-timed prior article, we finally have an approved intranasal device. This is exciting and the product is priced within reach of a lot of insurers – less so community programs unfortunately. The one other potential issue is the pharmacokinetic data for this product, which suggest that the recipient may be exposed to the equivalent of around five times the standard 0.4mg intramuscular dose. Hopefully this won’t be an issue at all – and perhaps will instead be helpful for the fentanyl overdoses  seen with increasing frequency – but we will have to keep close watch for problems related to precipitated withdrawal.

Brodrick JE, Brodrick CK, Adinoff B.
Am J Drug Alcohol Abuse. 2016 Jan 25:1-12. [Epub ahead of print]
Comment: Another legal review of naloxone access.

Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D.
J Addict Med. 2016 Jan 19. [Epub ahead of print]
Comment: I like the title of this article, as it hints at the primacy of medication.

Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO.
J Urban Health. 2016 Jan 22. [Epub ahead of print]
Comment: How can we use geocoding data to enhance the public health response to overdose surveillance?

Compton WM, Jones CM, Baldwin GT.
N Engl J Med. 2016 Jan 14;374(2):154-63. doi: 10.1056/NEJMra1508490. Review. No abstract available.
Comment: Interesting take on the trend of increasing heroin-related deaths. Most likely there is truth to both sides of this argument – opioid prescribing got lots of people hooked and taking away the opioids leaves a hole filled by illicit opioids.

Maldjian L, Siegler A, Kunins HV.
Subst Abus. 2016 Jan 5:0. [Epub ahead of print]
Comment: Happy we have these data, and the lack of an age or racial differentiation in knowledge is very promising. The conclusions – that we need to improve training – is based on a pre-set idea of what knowledge is necessary to effectively respond to an overdose. I’m not sure we know that, so it’s hard to say that the trainings are insufficient. Also, with regard to the finding that some participants didn’t know naloxone could reverse opioids besides heroin, I’m curious if that finding translates to some emergency medical providers as well...

Dilokthornsakul P, Moore G, Campbell JD, Lodge R, Traugott C, Zerzan J, Allen R, Page RL 2nd.
J Pain. 2015 Dec 22. pii: S1526-5900(15)00985-2. doi: 10.1016/j.jpain.2015.12.006. [Epub ahead of print]
Comment: Dose, use of methadone, substance use disorder, other psychiatric illness, benzodiazepine use, and number of pharmacies utilized.

Roe SS, Banta-Green CJ.
Subst Use Misuse. 2015 Dec 28:1-8. [Epub ahead of print]
Comment: Web-based naloxone training!

Erdmann A, Werner D, Hugli O, Yersin B.
Swiss Med Wkly. 2015 Dec 28;145:w14242. doi: 10.4414/smw.2015.14242. eCollection 2015.
Comment: Drug screening helps manage toxidromes in the ED.

Beheshti A, Lucas L, Dunz T, Haydash M, Chiodi H, Edmiston B, Ford C, Bohn N, Stein JH, Berrett A, Sobota B, Horzempa J.
Am Med J. 2015 Jul 9;6(1):9-13.
Comment: Naloxone emerging in West Virginia, which has a remarkably high rate of opioid overdose mortality.

Kennedy-Hendricks A, Richey M, McGinty EE, Stuart EA, Barry CL, Webster DW.
Am J Public Health. 2016 Feb;106(2):291-7. doi: 10.2105/AJPH.2015.302953. Epub 2015 Dec 21.
Comment: While we usually discuss health system-related interventions on this site, there have been a few times when law enforcement-related activities have resulted in many lives saved. The Florida example described here is one of those. Another was in 2007, when the DEA shut down a fentanyl manufacturer in Mexico, ending a dramatic spate of deaths on the eastern seaboard.

Uusküla A, Raag M, Vorobjov S, Rüütel K, Lyubimova A, Levina OS, Heimer R.
BMC Public Health. 2015 Dec 18;15(1):1255. doi: 10.1186/s12889-015-2604-6.
Comment: Exciting to see these important data. Unfortunately the health of drug users – and the ability to study or intervene – has only worsened in Russia.

Winstanley EL, Clark A, Feinberg J, Wilder CM.
Subst Abus. 2015 Dec 18:0. [Epub ahead of print]
Comment: Drug use is stigmatized and naloxone’s too expensive.

Oliva EM, Nevedal A, Lewis ET, McCaa MD, Cochran MF, Konicki PE, Davis CS, Wilder C.
Subst Abus. 2015 Dec 16:0. [Epub ahead of print]
Comment: Fascinating focus groups on naloxone among veterans.

Nambiar D, Agius PA, Stoové M, Hickman M, Dietze P.
Harm Reduct J. 2015 Dec 9;12:55. doi: 10.1186/s12954-015-0089-3.
Comment: Mortality rate was 1.0/100person-years, associated with prior incarceration, recent need for emergency care, and recent overdose. Only half of the deaths were likely accidental overdose, suggesting overall a lower rate of opioid overdose mortality than is standard in the literature – perhaps because 36% were in agonist maintenance treatment.

Howland RH.
J Psychosoc Nurs Ment Health Serv. 2015 Dec 1;53(12):11-4. doi: 10.3928/02793695-20151117-01.
Comment: Buprenorphine is safer than other opioids.

Bird SM, McAuley A, Perry S, Hunter C.
Addiction. 2015 Dec 7. doi: 10.1111/add.13265. [Epub ahead of print]
Comment: Very exciting data from Scotland supporting naloxone among inmates pre-release to reduce opioid-related mortality.

Frank JW, Levy C, Calcaterra SL, Hoppe JA, Binswanger IA.
J Med Toxicol. 2015 Nov 30. [Epub ahead of print]
Comment: Tough to interpret these data. Only a minority of opioid overdose cases had naloxone administered – this makes sense since overdose can often be safely managed without naloxone in monitored settings. In 14% of cases where naloxone was administered, an opioid agonist was also provided – this would surely be a high rate of iatrogenic overdose … Can’t access full article.

Pavarin RM.
Subst Use Misuse. 2015;50(13):1690-6. doi: 10.3109/10826084.2015.1027932. Epub 2015 Nov 23.
Comment: The mortality rate was even higher among the cohort of Italian heroin users who sought treatment compared to those just accessing emergency care. This is fascinating. And only 17% of deaths were from opioid overdose.

Strickler K.
Iowa Med. 2015 Summer;105(3):10-1. No abstract available.
Comment: Can’t access and no abstract.

Klimas J, Egan M, Tobin H, Coleman N, Bury G.
BMC Med Educ. 2015 Nov 20;15(1):206. doi: 10.1186/s12909-015-0487-y.
Comment: Authors utilized the British OOKS/OOAS scales to test their training efficacy.

Rogers JS, Rehrer SJ, Hoot NR.
J Emerg Med. 2015 Nov 14. pii: S0736-4679(15)01148-8. doi: 10.1016/j.jemermed.2015.10.014. [Epub ahead of print]
Comment: Case report of acetyl-fentanyl overdose targeted at emergency providers.

Larney S, Degenhardt L, Farrell M.
Addiction. 2015 Nov 21. doi: 10.1111/add.13208. [Epub ahead of print] No abstract available.
Comment: Opioid agonist treatment in prison helps too.

Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA.
Harm Reduct J. 2015 Nov 14;12:54. doi: 10.1186/s12954-015-0088-4.
Comment: 29% of participants tested positive for fentanyl while 73% denied any use – this adulterant is not good news.

Heimer R, Lyubimova A, Barbour R, Levina OS.
Int J Drug Policy. 2016 Jan;27:97-104. doi: 10.1016/j.drugpo.2015.10.001. Epub 2015 Oct 19.
Comment: Even when in the illicit market (because it’s not legal in Russia), methadone use is associated with reduced HIV risk behaviors.

Jones A, Hayhurst KP, Millar T, Pierce M, Dunn G, Donmall M.
Eur Addict Res. 2016;22(3):145-52. doi: 10.1159/000438987. Epub 2015 Nov 17.
Comment: Improvements in drug use behaviors were not mediated by whether or not treatment was due to criminal justice referral.

Wilder CM, Miller SC, Tiffany E, Winhusen T, Winstanley EL, Stein MD.
J Addict Dis. 2016 Jan-Mar;35(1):42-51. doi: 10.1080/10550887.2016.1107264.
Comment: Pain patients underestimate overdose risk.

Wan WY, Weatherburn D, Wardlaw G, Sarafidis V, Sara G.
Int J Drug Policy. 2016 Jan;27:74-81. doi: 10.1016/j.drugpo.2015.09.012. Epub 2015 Oct 23.
Comment: Overall, it appears that more drug supply leads to more overdoses. This is a critical issue certainly worthy of additional investigation.

Wise J.
BMJ. 2015 Sep 3;351:h4754. doi: 10.1136/bmj.h4754. No abstract available.
Comment: Increased deaths in England and Wales is concerning. A smaller increase also occurred in Scotland, again suggesting that naloxone programming – while perhaps able to blunt spikes in mortality – can’t avoid the problem altogether.

Beletsky L.
Am J Prev Med. 2015 Mar;48(3):357-9. doi: 10.1016/j.amepre.2014.09.011. Epub 2014 Dec 26. Review. No abstract available.
Comment: Great commentary, emphasizing both the pricing of naloxone and the need for a broader program to prevent overdose mortality.


Monday, 27 July 2015

PubMed Update March - May 2015

Three months. 46 papers. I’m already a month behind.

Dahlem CH, Horstman MJ, Williams BC.
J Am Assoc Nurse Pract. 2015 Mar 26. doi: 10.1002/2327-6924.12249. [Epub ahead of print]
Comments: Naloxone programs have been providing kits to settings where homeless people receive services for many years. This is a description of a program at a homeless health clinic.

Christoffersen DJ, Brasch-Andersen C, Thomsen JL, Worm-Leonhard M, Damkier P, Brøsen K.
Forensic Sci Med Pathol. 2015 Jun;11(2):193-201. doi: 10.1007/s12024-015-9673-9. Epub 2015 Mar 24.
Comments: It’s been awhile since we had a forensics paper here. I think this is a novel method of identifying enantiomers.

Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA.
Am J Public Health. 2015 May;105(5):e51-7. doi: 10.2105/AJPH.2014.302546. Epub 2015 Mar 19.
Comments: Stunningly low rate of drug overdose mortality in this cohort of prisoners in Georgia. This is one of the first times I’ve seen a paper on opioid overdose find radically different results in a different setting. I can’t access for details.

Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA.
Subst Abus. 2015 Mar 16:1-14. [Epub ahead of print]
Comments: A review toward the end of using community distribution data to build clinical care naloxone prescription.

Hser YI, Evans E, Grella C, Ling W, Anglin D.
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89. doi: 10.1097/HRP.0000000000000052.
Comments: This is a systematic review of long-term studies of opioid users. Among many fascinating data reported, the length of time not using a drug of choice increases the likelihood of continuing to not use that drug. This seems obvious to many, but I don’t believe it’s been documented before. Good read for anyone looking to understand some of the longitudinal outcome data.


Connery HS.
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75. doi: 10.1097/HRP.0000000000000075.
Comments: Nice review of treatment options for opioids. Strong evidence for methadone and buprenorphine. Weak evidence of naltrexone therapies – with oral increasing mortality and early but favorable evidence for injectable naltrexone.

Dennis BB, Bawor M, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.
Syst Rev. 2015 Apr 16;4(1):49. doi: 10.1186/s13643-015-0042-2.
Comments: A paper describing a planned paper. Hmm.

Aljarallah S, Al-Hussain F.
BMC Neurol. 2015 Apr 30;15(1):69. doi: 10.1186/s12883-015-0320-6.
Comments: Usually we see this after opioid overdose. Interesting.

Woodcock EA, Lundahl LH, Burmeister M, Greenwald MK.
Am J Addict. 2015 Apr 24. doi: 10.1111/ajad.12187. [Epub ahead of print]
Comments: The 118G allele was once associated with better responsiveness to naltrexone for alcohol dependence. Interesting now to see it associated with more troubling heroin use patterns. Can’t access full article for details.

Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M, Kelley G.
Pain Ther. 2015 Apr 25. [Epub ahead of print]
Comments: The naloxone autoinjector is easier to use than the jerry-rigged intranasal device.

Faul M, Dailey MW, Sugerman DE, Sasser SM, Levy B, Paulozzi LJ.
Am J Public Health. 2015 Apr 23:e1-e7. [Epub ahead of print]
Comments: Basic life support-trained EMTs generally don’t administer naloxone – and they deal with most overdoses in rural areas.

Walley AY.
Prev Med. 2015 Apr 18. pii: S0091-7435(15)00109-7. doi: 10.1016/j.ypmed.2015.04.004. [Epub ahead of print]
Comments: Yup.

Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF.
JAMA Intern Med. 2015 Apr 20. doi: 10.1001/jamainternmed.2015.0914. [Epub ahead of print]
Comments: Being that I’m not a pharmaceutical company, my interest is in the welfare of people regardless of what they are putting into their bodies. Oxycodone, morphine, methadone, hydromorphone, oxymorphone, or heroin. The clear uptick in heroin use and heroin (as well as overall opioid) overdose mortality began when we started using injection-deterrent formulations (the formulations only address injection – not other potentially problematic use patterns).

Moore C, Lloyd G, Oretti R, Russell I, Snooks H.
Emerg Med J. 2015 May;32(5):421-2. doi: 10.1136/emermed-2015-204877.3.
Comments: Great idea. I believe the naloxone program in Inverness, Scotland, first inspired this idea by following up with overdose patients in the month after a paramedic reversal.

Molfenter T, Sherbeck C, Zehner M, Quanbeck A, McCarty D, Kim JS, Starr S.
Subst Abuse Treat Prev Policy. 2015 Mar 28;10(1):13. doi: 10.1186/s13011-015-0009-2.
Comments: Unfortunately there are multiple barriers. Physician availability, reimbursement, etc.

Compton WM, Boyle M, Wargo E.
Prev Med. 2015 Apr 11. pii: S0091-7435(15)00103-6. doi: 10.1016/j.ypmed.2015.04.003. [Epub ahead of print]
Comments: Review of prescription opioid use problems and responses, including agonist treatment and naloxone.

Kim HK, Nelson LS.
Expert Opin Drug Saf. 2015 Apr 12:1-10. [Epub ahead of print]
Comments: Naloxone is safe. Don’t use massive doses or people go into severe withdrawal. Lay programs generally use 0.4mg intramuscular. The intranasal 2mg dose has some variability, but is probably equivalent to 0.3-0.4mg intramuscular for many people.

Davis CS, Walley AY, Bridger CM.
J Law Med Ethics. 2015 Mar;43 Suppl 1:19-22. doi: 10.1111/jlme.12208.
Comments: Laws aren’t enough. Providers need education and the formulations are problematic.

Furlano E.
EMS World. 2014 Oct;43(10):28-30, 32-4. No abstract available.
Comments: Basic life support-trained providers should have naloxone.

Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO.
Addiction. 2015 Apr 27. doi: 10.1111/add.12961. [Epub ahead of print]
Comments: Among recipients of take-home naloxone, those most likely to report using it to reverse an overdose are active drug users themselves. This emphasizes the top priority of getting naloxone into the hands of drug users.

Degenhardt L, Larney S, Randall D, Burns L, Hall W.
Addiction. 2014 Jan;109(1):90-9. doi: 10.1111/add.12337. Epub 2013 Oct 9.
Comments: Another stellar longitudinal paper. Overdose is of course the driver of mortality, but major organ disease-related mortality becomes a close competitor after age 45. Suicide is common, accounting for 10-15% of mortality. Another must read.

Espelt A, Barrio G, Álamo-Junquera D, Bravo MJ, Sarasa-Renedo A, Vallejo F, Molist G, Brugal MT.
Eur Addict Res. 2015 May 28;21(6):300-306. [Epub ahead of print]
Comments: Authors of this study from Madrid and Barcelona come to a similar conclusion as some older papers on heroin overdose – that approximately 4% are fatal. Of note, these are youngheroin users, which implies events that are more likely to be witnessed. Mortality is likely higher among older users, who are more likely to be socially isolated, leading to an overall estimated mortality of approximately 10%.

Wakeland W, Nielsen A, Geissert P.
Am J Drug Alcohol Abuse. 2015 May 18:1-11. [Epub ahead of print]
Comments: I can’t access. I believe this was also presented as a poster at CPDD this year.

Mounteney J, Giraudon I, Denissov G, Griffiths P.
Int J Drug Policy. 2015 Apr 17. pii: S0955-3959(15)00097-3. doi: 10.1016/j.drugpo.2015.04.003. [Epub ahead of print]
Comments: Ugh. Fentanyl is scary because it is dosed in micrograms – which is really hard to do safely, especially in an illicit market.

Meiman J, Tomasallo C, Paulozzi L.
Drug Alcohol Depend. 2015 Jul 1;152:177-184. doi: 10.1016/j.drugalcdep.2015.04.002. Epub 2015 Apr 18.
Comments: Most states/localities saw a stark inflection point in heroin overdose events after 2010; that inflection seems less pronounced in this study.

Sarasa-Renedo A, Espelt A, Folch C, Vecino C, Majó X, Castellano Y, Casabona J, Brugal MT; Redan Study Group.
Gac Sanit. 2014 Mar-Apr;28(2):146-54. doi: 10.1016/j.gaceta.2013.10.012. Epub 2014 Jan 10.
Comments: Study out of Barcelona looking at predictors of less overdose prevention knowledge.

Farrell M, Marsden J, Strang J.
Addiction. 2015 Jul;110 Suppl 2:54-8. doi: 10.1111/add.12910.
Comments: Review of Griffith Edwards’s work in the 1960s and 1970s addressing the transition from correctional to community settings. Important prelude to what’s been done over the past 20 years and what we hope will be achieved in the years to come.

Strang J.
Addiction. 2015 Jul;110 Suppl 2:27-35. doi: 10.1111/add.12904.
Comments: Let’s move on to implementation science?

Fareed A, Buchanan-Cummings AM, Crampton K, Grant A, Drexler K.
Am J Addict. 2015 Jun 3. doi: 10.1111/ajad.12230. [Epub ahead of print]
Comments: Report out of the Veterans’ Administration, which is admirably taking on overdose prevention.

Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N.
Lancet. 2015 May 28. pii: S0140-6736(14)62338-2. doi: 10.1016/S0140-6736(14)62338-2. [Epub ahead of print]
Comments: With respect to the excellent investigators, are we really living in a world where this kind of study is either needed or permitted? “Usual care” as forced withdrawal of a life-saving medication is … leaving me speechless.

Marteau D, McDonald R, Patel K.
BMJ Open. 2015 May 29;5(5):e007629. doi: 10.1136/bmjopen-2015-007629.
Comments: Buprenorphine is six times safer than methadone with regard to risk of drug overdose death. This is, of course, observational, and does not take into account differing characteristics of opioid dependent persons that may drive them to one treatment or another. Methadone is an invaluable tool for a large proportion of individuals in need.

Coe MA, Walsh SL.
Prev Med. 2015 May 27. pii: S0091-7435(15)00175-9. doi: 10.1016/j.ypmed.2015.05.016. [Epub ahead of print]
Comments: Commentary on the concept of co-prescribing naloxone to pain patients on opioids.

Robertson JR, Robertson AR.
Curr Opin Psychiatry. 2015 Jul;28(4):286-91. doi: 10.1097/YCO.0000000000000174.
Comments: Review of substance use issues affecting family practice providers.

Agarin T, Trescot AM, Agarin A, Lesanics D, Decastro C.
Pain Physician. 2015 May-Jun;18(3):E307-22.
Comments: Nobody knows yet.

Dwyer K, Walley AY, Langlois BK, Mitchell PM, Nelson KP, Cromwell J, Bernstein E.
West J Emerg Med. 2015 May;16(3):381-284. doi: 10.5811/westjem.2015.2.24909. Epub 2015 Apr 1.
Comments: Nice initial observational study of naloxone from emergency departments. Low response rate.

Sansone RA, Sansone LA.
Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):32-6.
Comments: Buprenorphine is hard to overdose on in the absence of sedatives such as benzodiazepines. There is diversion, but largely to individuals already dependent on opioids who are seeking to stave off withdrawal or often self-detox. It’s about time we moved on to more sophisticated diversion research, which differentiated the type of prescription drug diversion most people have engaged in – like sharing your leftover amoxicillin or hydrocortisone cream – and more dangerous forms.

Clausen T.
Addiction. 2015 Jun;110(6):1006-7. doi: 10.1111/add.12922. No abstract available.
Comments: Nice commentary on the role and importance of agonist medications in treating opioid use disorder.

Weiss RC, Bazalo GR, Thomson H, Edwards E.
Manag Care. 2015 Feb;24(2):41-8.
Comments: I can no longer claim to have the only mathematical model of opioid overdose! This is a model from the payer perspective. Funded and co-authored by the manufacturers of the naloxone autoinjector.

Bury G.
Ir Med J. 2015 Mar;108(3):70. No abstract available.
Comments: can’t access.

Pap Á, Hegedűs K.
Orv Hetil. 2015 Mar 1;156(9):352-7. doi: 10.1556/OH.2015.30091. Review. Hungarian.
Comments: Review of overdose / prevention in Hungary.

Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM.
JAMA Intern Med. 2015 Mar;175(3):420-7. doi: 10.1001/jamainternmed.2014.6294.
Comments: More on the potential hazards of methadone when used for chronic noncancer pain. I remain mixed on these data. There is a mechanistic argument that methadone is more risky, but at the same time it is generally prescribed to lower income patients with less optimal insurance that doesn’t cover the more expensive long-acting opioid formulations. It’s hard to convincingly disentangle the risks of the population from the risks of the drug.

Bernstein HG, Trübner K, Krebs P, Dobrowolny H, Bielau H, Steiner J, Bogerts B.
Acta Histochem. 2014 Jan;116(1):182-90. doi: 10.1016/j.acthis.2013.07.006. Epub 2013 Aug 13.
Comments: Interesting. Not sure what to make of this one.